近些年來，免疫耐受治療癌癥和自發(fā)免疫疾病的臨床應(yīng)用引起了人們廣泛的關(guān)注,。免疫系統(tǒng)的特點(diǎn)是能夠區(qū)別自身與非自身的抗原,，它能夠?qū)ψ陨砑?xì)胞產(chǎn)生耐受,，而對(duì)病原菌或者惡性細(xì)胞產(chǎn)生免疫應(yīng)答,。這種耐受和免疫之間的關(guān)系是動(dòng)態(tài)的，在體內(nèi)能夠被很好的平衡,，如果動(dòng)態(tài)平衡的天平傾向任何一端都有可能導(dǎo)致有害的病理狀況,，比如產(chǎn)生自身免疫反應(yīng)，感染等等。
基于免疫方法的癌癥治療當(dāng)中,，免疫耐受是一個(gè)很重要的因素,。癌癥的微環(huán)境是動(dòng)態(tài)的，很多細(xì)胞同其他細(xì)胞互作,，在這樣的環(huán)境當(dāng)中,，大多數(shù)的免疫治療缺乏克服免疫耐受的能力。研究發(fā)現(xiàn)耐受性細(xì)胞可以治療非正常免疫反應(yīng)帶來的各種紊亂,，比如慢性疾病,，自發(fā)免疫疾病等等。而且細(xì)胞免疫治療可以同干細(xì)胞治療一同抑制自發(fā)的,、移植排斥宿主的反應(yīng),。但是還需要注意，非特異性和不可控制的免疫耐受可能會(huì)讓易病人群有機(jī)會(huì)感染疾病,。
潛在的細(xì)胞治療，包括免疫治療和細(xì)胞替代療法,，由于一些因素而受到限制?，F(xiàn)在多能干細(xì)胞的發(fā)展能夠產(chǎn)生更多的自體同源耐受性細(xì)胞。更好的理解免疫耐受在不同的實(shí)驗(yàn)設(shè)置和動(dòng)物模型中存在和穩(wěn)定的機(jī)制,，將有助于我們?nèi)フ{(diào)控免疫耐受細(xì)胞在體內(nèi)和體外的不同發(fā)展,，為細(xì)胞耐受治療提供動(dòng)力。
相關(guān)論文發(fā)表在愛思唯爾期刊《先進(jìn)藥物輸送評(píng)論》（Advanced Drug Delivery Reviews）上,。（科學(xué)新聞雜志 周媛媛/編譯）
生物谷推薦原始出處：
（Advanced Drug Delivery Reviews）,，Volume 60, Issue 2, 14 January 2008, Pages 91-105，Ping-Ying Pan,，Shu-Hsia Chen
Advancements in immune tolerance
Ping-Ying Pan, a, , Junko Ozaoa, Zuping Zhoua and Shu-Hsia Chen, a,
aDepartment of Gene and Cell Medicine, Box 1946, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY, 10029, USA
Received 2 August 2007; accepted 14 August 2007. Available online 5 October 2007.
Abstract
In recent years, considerable attention has been given to immune tolerance and its potential clinical applications for the treatment of cancers and autoimmune diseases, and the prevention of allo-graft rejection and graft-versus-host diseases. Advances in our understanding of the underlying mechanisms of establishment and maintenance of immune tolerance in various experimental settings and animal models, and in our ability to manipulate the development of various immune tolerogenic cells in vitro and in vivo, have generated significant momentum for the field of cell-based tolerogenic therapy. This review briefly summarizes the major tolerogenic cell populations and their mechanisms of action, while focusing mainly on potential exploitation of their tolerogenic mechanisms for clinical applications.
